key: cord-1033680-szwf8ru5
authors: Rossignol, Julien; Ouedrani, Amani; Livideanu, Cristina Bulai; Barete, Stéphane; Terriou, Louis; Launay, David; Lemal, Richard; Greco, Celine; Frenzel, Laurent; Meni, Cecile; Bodemere-Skandalis, Christine; Polivka, Laura; Collange, Anne-Florence; Hachichi, Hassiba; Bouzourine, Sonia; Messaoud, Djazira Nait; Negretto, Mathilde; Vendrame, Laurence; Jambou, Marguerite; Gousseff, Marie; Durupt, Stéphane; Lega, Jean-Christophe; Durand, Jean-Marc; Gaudy, Caroline; Damaj, Gandhi; Gourin, Marie-Pierre; Hamidou, Mohamed; Bouillet, Laurence; Le Mouel, Edwige; Maria, Alexandre; Zunic, Patricia; Cabrera, Quentin; Vincent, Denis; Lavigne, Christian; Riviere, Etienne; Gourguechon, Clement; Brignier, Anne; Lhermitte, Ludovic; Molina, Thierry Jo; Bruneau, Julie; Agopian, Julie; Dubreuil, Patrice; Ranta, Dana; Mania, Alexandre; Arock, Michel; Staropoli, Isabelle; Tournilhac, Olivier; Lortholary, Olivier; Schwartz, Olivier; Chatenoud, Lucienne; Hermine, Olivier
title: Effective anti-SARS-CoV-2 immune response in patients with clonal mast cell disorders.
date: 2022-01-21
journal: J Allergy Clin Immunol Pract
DOI: 10.1016/j.jaip.2021.12.038
sha: 4b3015ea017657197aba6215644228ab5228c90b
doc_id: 1033680
cord_uid: szwf8ru5

Background Mast cells are key players in innate immunity and the Th2 adaptive immune response. The latter counterbalances the Th1 response, which is critical for antiviral immunity. Clonal mast cell activation disorders (cMCADs, such as mastocytosis and clonal mast cell activation syndrome) are characterized by abnormal mast cell accumulation and/or activation. No data on the antiviral immune response in patients with MCADs have been published. Objective To study a comprehensive range of outcomes in cMCAD patients with PCR- or serologically confirmed COVID-19 and to characterize the specific anti-SARS-CoV-2 immune response in this setting. Methods Clinical follow-up and outcome data were collected prospectively over a 12-month period by members of the French Centre de Référence des Mastocytoses rare disease network. Anti-SARS-CoV-2-specific T-cell activity was measured with an enzyme-linked immunospot assay, and humoral responses were evaluated by assaying circulating levels of specific IgG, IgA and neutralizing antibodies. Results Overall, 32 cMCAD patients were evaluated. None required non-invasive or mechanical ventilation. Two patients were admitted to hospital for oxygen and steroid therapy. The SARS-CoV-2-specific immune response was characterized in 21 of the 32 patients. Most had high counts of circulating SARS-CoV-2-specific, interferon (IFN)-γ-producing T-cells and high titers of neutralizing anti-spike IgGs. The patients frequently showed spontaneous T-cell IFN-γ production in the absence of stimulation; this production was correlated with basal circulating tryptase levels (a marker of the mast cell burden). Conclusion Patients with cMCADs might not be at risk of severe COVID-19 – perhaps due to their spontaneous production of IFN-γ.

Clinical follow-up and outcome data were collected prospectively over a 12-month 150 period by members of the French Centre de Référence des Mastocytoses rare disease network. 151 Anti-SARS-CoV-2-specific T-cell activity was measured with an enzyme-linked immunospot 152 assay, and humoral responses were evaluated by assaying circulating levels of specific IgG, 153 IgA and neutralizing antibodies. What does this article add to our knowledge? 170 In a comprehensive, prospective study, we did not observe any cases of severe COVID-19 171 among groups of patients with clonal mast cell activation disorders. The patients showed effective anti-coronavirus immune responses. Spontaneous interferon gamma release (in the 173 absence of T-cell stimulation) was observed frequently in patients with clonal mast cell 174 activation disorders and was correlated with the basal tryptase level.

How does this study impact current management guidelines? 176 The observed spontaneous production of interferon gamma (correlated with the mast cell pathophysiological data suggests that interferons (IFNs) have a major role in disease control.

These includes type I IFN (produced by plasmacytoid dendritic cells) and type III IFN (IFN-) 215 produced by T-cells from the adaptive immune system in the early and late phases of the 216 disease, respectively 5-8 . 217 One can hypothesize that the MCs' ability to drive Th2 responses 9-11 (which counterbalance 218 Th1 responses) might impair antiviral immunity in patients with cMCADs. Furthermore, 219 histamine blocks the in vitro activity of plasmacytoid dendritic cells; in vivo, this might weaken 220 antiviral immune responses 12 . MCs might therefore (i) contribute to COVID-19-induced inflammation by releasing pro-inflammatory cytokines such as interleukin (IL-)1, IL-6, and 222 tumor necrosis factor (TNF) and (ii) exacerbate COVID-19 lung damage via degranulation 13,14 .

If so, this would render patients with cMCAD more susceptible to severe COVID-19.

Over a 12-month period, members of the French Centre de Référence des Mastocytoses 225 (CEREMAST) rare disease network collected data prospectively on the patients with cMCADs 226 (MMAS and mastocytosis) and a positive PCR test or serology assay for SARS-CoV-2. Here, 227 we describe the patients' clinical course, outcomes, and immunologic characteristics.

The members of the CEREMAST network collected data prospectively from patients with a 231 cMCAD and COVID-19, as documented by either a positive SARS-CoV-2 PCR test on a nasal 232 swab or symptoms suggestive of COVID-19 and a positive anti-SARS-CoV-2 serology assay.

Patients with symptoms suggestive of COVID-19 but who lacked a positive PCR test or a 234 positive serology assay for SARS-CoV-2 infection were excluded from the study. questionnaire was designed to collect data on any signs of MC activation displayed during 242 COVID-19, the patient's treatments, and the patient's specific signs and outcomes related to 243 COVID-19. We then classified the patients as having had proven COVID-19 or not ( Figure 1 ). collected data on patients who had presented with COVID-19 but had not replied to the 246 questionnaire. To check that we had not missed any severe cases (at least in the greater Paris 247 region, as a proxy for national coverage), we also searched the French national hospital were derived from a peptide scan through the SARS-CoV-2 spike glycoprotein (two pools: S1 290 for the N-terminal fragment, and S2 for the C-terminal fragment), membrane protein (M), 291 nucleoprotein (N), envelope small membrane protein (E), and ORF3a protein. We also tested peptide pools derived from the spike glycoprotein of the common human alpha-coronaviruses 293 (HCoV-229E and HCoV-NL63) and beta-coronaviruses (HCoV-OC43 and HCoV-HKU1).

The humoral immune response (including the production of anti-spike SARS-CoV-2 IgG, IgA 295 antibodies and the neutralizing ability of anti-spike IgGs) was characterized using previously 296 described S-flow and S-pseudotype neutralization assays 17 . Briefly, the S-flow assay used 297 human embryonic kidney (HEK)293T cells transduced with the SARS-CoV-2 spike protein.

Cells were incubated with sera from patients (dilution: 1:300) and stained with either anti-IgG 299 or anti-IgA antibodies. The fluorescent signal was measured by flow cytometry. For the S-300 pseudotype neutralization assay, pseudotyped viruses carrying SARS-CoV-2 spike protein 301 were used. The viral pseudotypes were incubated with the sera to be tested (dilution: 1:100), 302 added to transduced HEK293T cells expressing ACE2, and incubated for 48 h at 37°C. The 303 assay measures the anti-S antibodies' ability to neutralize an infection, as described elsewhere 17 . 305 For each group, the number of patients, the median age and the sex ratio are reported in 306 Supplemental Table E1 . Four control groups were used in this study: (i) non-MCAD patients 307 convalescing from mild-to-moderate (n=17) and (ii) severe (n=15) forms of COVID-19 and 308 who had already been evaluated with SARS-CoV-2 ELISpot and serology assays in Necker 

In parallel with the ELISpot assay, we also used a high-sensitivity assay (the S-flow assay) to Interestingly, inspection of the ELISpot plates showed that the background signal was 400 significantly higher in cMCAD wells than in non-cMCAD control wells. In wells containing 401 non-stimulated PBMCs in culture medium but with no peptide pools, we counted more than 10 402 small spots per 2x10 5 CD3+ cells in 10 of the 24 cMCAD patients (with or without a history of 403 COVID-19), 3 of the 31 non-cMCAD controls (p=0.009 in Fisher's exact test), and 2 of the 11 404 controls with idiopathic MCAS ( Figure 3A ).

It should be noted that the SARS-CoV-2-specific spots were much larger and more intense than 406 To the best of our knowledge, the present study is the first to have investigated the antiviral cMCAD: clonal mast cell activation disorder. The tested SARS-CoV-2 peptide pools were derived from a peptide scan through the SARS-CoV-2 spike glycoprotein (S1: N-terminal fragment, S2: C-terminal fragment), membrane protein (M), nucleoprotein (N), and ORF3a protein (AP3a). The negative controls were PBMCs in culture medium alone, and the positive controls were PHA and the CEFX Ultra SuperStim Pool. Results were expressed as the number of spot-forming cells (SFCs)/10 6 CD3+ T-cells after subtraction of the background values from wells with non-stimulated cells. All differences between the non-COVID-19 and COVID-19 groups were statistically significant (p<0.001). cMCADs: convalescent patients with clonal mast cell activation disorders. Non-cMCAD m-m COVID-19: non-cMCAD control patients convalescing from a mild-to-moderate form of COVID-19 (n=17). Non-cMCADs severe COVID-19: non-cMCAD control patients convalescing from a severe form of COVID-19 (n=15). Non-cMCAD non-COVID-19: non-cMCAD, non-COVID-19 controls (n=15). ns: non-significant; *, p<0.05; ****, p<0.0001. cMCADs: patients with clonal mast cell activation disorders, convalescing from mild-tomoderate (m-m) or severe COVID-19.

Review Article Mastocytosis : 2016 updated WHO 517 classi fi cation and novel emerging treatment concepts

Systemic 519 mastocytosis in 342 consecutive adults : survival studies and prognostic factors 520

Systemic mastocytosis in 342 consecutive adults : survival studies and prognostic 521 factors

Empty circles: no history of COVID-19. Filled circles: history of COVID-19. Pictures of ELISpot assays. B: A well with non

A well with non-stimulated PBMCs from a COVID-19 cMCAD patient. D: A well with PBMCs from a COVID-19 non-cMCAD control after stimulation for 18-20 h with individual 15-mer 11-aa overlapping peptide pools derived from the SARS-CoV

N-terminal fragment spike protein. E: A well with PBMCs from a COVID-19 cMCAD patient after stimulation with individual 15-mer 11-aa overlapping peptide pools derived from the SARS-CoV-2 N-terminal fragment spike protein

Correlation between basal tryptase level (µg/L) and spontaneous IFN-γ production (spot-forming cells (SFCs)/2x10 5 CD3), as observed in ELISpot assays